Related Experiment Video
Updated: Jul 24, 2025
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
Published on: August 14, 2018
Localization of EGFR Mutations in Non-small-cell Lung Cancer Tissues Using Mutation-specific PNA-DNA Probes
Hajime Shigeto1, Haruo Miyata2, Tadashi Ashizawa2
1Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Kagawa, Japan.
Background/Aim:
Epidermal growth factor receptor (EGFR) signaling inhibitors are potent therapeutic agents for EGFR-mutant non-small-cell lung cancer, but the effects of such inhibitors on the localization of EGFR mutations in tumor tissues remain to be elucidated. Thus, a simple and efficient technology for the detection of mutations in tumor tissue specimens needs to be developed.
Materials And Methods:
Using an EGFR mutation-specific peptide nucleic acid (PNA)-DNA probe, the EGFR mutation-positive part of whole NSCLC tissues was visualized by immunofluorescence. Formalin-fixed paraffin-embedded sections obtained from A549, NCI-H1975, HCC827 and PC-9 tumors transplanted into nude mice were subjected to staining using PNA-DNA probes specific for the mRNA sequences producing the L858R, del E746-A750 and T790M mutations.
Results:
The probes for the L858R mutation showed intense positive staining in H1975 cells, and the probe for the del E746-A750 mutation exhibited positive staining specifically in HCC827 and PC-9 tumors. On the other hand, A549 tumors without EGFR mutation did not show any significant staining for any PNA-DNA probe. In combination staining, the addition of cytokeratin stain increased the positive staining rate of each PNA-DNA probe. In addition, the positive staining rate of the probes for the L858R mutation was comparable to that of the antibody to EGFR L858R mutated protein.
Conclusion:
PNA-DNA probes specific for EGFR mutations might be useful tools to detect heterogeneous mutant EGFR expression in cancer tissues and efficiently evaluate the effect of EGFR signaling inhibitors on tissues of EGFR-mutant cancer.
Insights
New peptide nucleic acid (PNA)-DNA probes can detect epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) tissues. This technology helps visualize mutant EGFR expression and assess treatment effects in EGFR-mutant NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Epidermal growth factor receptor (EGFR) signaling inhibitors are crucial for treating EGFR-mutant non-small-cell lung cancer (NSCLC).
- The impact of these inhibitors on the spatial distribution of EGFR mutations within tumor tissues is not well understood.
- There is a need for efficient methods to detect EGFR mutations directly in tumor specimens.
Purpose of the Study:
- To develop and validate a simple, efficient technology for detecting EGFR mutations in NSCLC tissues.
- To visualize the localization of specific EGFR mutations (L858R, del E746-A750, T790M) within tumor tissues.
- To assess the utility of this technology in evaluating the effects of EGFR signaling inhibitors.
Main Methods:
- Utilized EGFR mutation-specific peptide nucleic acid (PNA)-DNA probes for immunofluorescence visualization.
- Applied probes to formalin-fixed paraffin-embedded NSCLC tumor sections from xenografts (A549, H1975, HCC827, PC-9).
- Performed staining for specific mutations (L858R, del E746-A750, T790M) and combined with cytokeratin staining.
Main Results:
- PNA-DNA probes specifically detected L858R mutations in H1975 cells and del E746-A750 mutations in HCC827 and PC-9 tumors.
- A549 tumors, lacking EGFR mutations, showed no significant staining.
- Combined staining with cytokeratin improved detection rates, and L858R probe results correlated with anti-EGFR L858R mutated protein antibody staining.
Conclusions:
- EGFR mutation-specific PNA-DNA probes are effective tools for detecting heterogeneous mutant EGFR expression in cancer tissues.
- This technology can be used to evaluate the impact of EGFR signaling inhibitors on tumor tissues.
- The method offers a valuable approach for personalized medicine in EGFR-mutant NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:16Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015